---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-046731"
form_type: "8-K"
ticker: "PDSB"
cik: "0001472091"
company_name: "PDS Biotechnology Corp"
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:25:23.040978+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# PDS Biotech reports Q3 net loss $10.7M; modifies Phase 3 trial design to cut costs

## Summary
- Net loss of $10.7M ($0.29/share) vs $10.8M ($0.35/share) in Q3 2023; operating expenses declined slightly.
- Cash and equivalents $49.8M as of Sept 30, 2024; cash runway supports VERSATILE-003 launch.
- Phase 3 VERSATILE-003 trial design modified: ~350 patients, 2:1 randomization, overall survival primary endpoint.
- Amended IND submitted Nov 2024; FDA clearance expected by mid-Dec; site activation targeted Q1 2025.
- R&D expenses $6.8M (+$0.4M YoY) on higher manufacturing; G&A $3.4M (-$0.7M YoY) on lower personnel costs.

## SEC filing metadata
- accession: 0001140361-24-046731
- form_type: 8-K
- ticker: PDSB
- cik: 0001472091
- company_name: PDS Biotechnology Corp
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472091/000114036124046731/0001140361-24-046731-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472091/000114036124046731/ef20038649_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-046731
- JSON: https://secwatch.observer/filing/0001140361-24-046731.json
- Plain text: https://secwatch.observer/filing/0001140361-24-046731.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.